Andrew Polovin Sells 7,927 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 7,927 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $56.00, for a total value of $443,912.00. Following the completion of the sale, the executive vice president owned 138,140 shares in the company, valued at $7,735,840. This represents a 5.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Andrew Polovin also recently made the following trade(s):

• On Tuesday, August 18th, Andrew Polovin sold 22,148 shares of Tempus AI stock. The stock was sold at an average price of $49.61, for a total value of $1,098,762.28.

Tempus AI Trading Up 8.8%

Tempus AI stock traded up $5.40 during midday trading on Thursday, reaching $66.65. 20,103,049 shares of the stock traded hands, compared to its average volume of 5,600,288. The firm has a market cap of $12.03 billion, a PE ratio of -46.28 and a beta of 3.58. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The company has a 50-day simple moving average of $52.44 and a two-hundred day simple moving average of $51.21. Tempus AI, Inc. has a 12-month low of $40.77 and a 12-month high of $104.32.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.22) earnings per share. Research analysts expect that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Stifel Nicolaus cut their target price on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating on the stock in a research note on Monday, August 3rd. Freedom Capital raised shares of Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. BTIG Research boosted their price target on shares of Tempus AI from $70.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday. Piper Sandler cut their price objective on Tempus AI from $58.00 to $56.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 4th. Finally, Wall Street Zen upgraded Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Nine analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $65.69.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TEM. Headlands Technologies LLC purchased a new position in shares of Tempus AI in the 2nd quarter valued at about $2,689,000. Public Employees Retirement System of Ohio purchased a new stake in Tempus AI during the second quarter worth approximately $1,775,000. Monetta Financial Services Inc. purchased a new stake in Tempus AI during the second quarter worth approximately $1,159,000. Handelsbanken Fonder AB boosted its holdings in Tempus AI by 4.1% in the second quarter. Handelsbanken Fonder AB now owns 32,900 shares of the company’s stock valued at $1,906,000 after purchasing an additional 1,300 shares in the last quarter. Finally, CoreCap Advisors LLC boosted its holdings in Tempus AI by 293.4% in the second quarter. CoreCap Advisors LLC now owns 1,019 shares of the company’s stock valued at $59,000 after purchasing an additional 760 shares in the last quarter. 24.22% of the stock is owned by institutional investors and hedge funds.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
• Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
• Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.